Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted…
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany,...
Nasdaq GlobeNewswire
27/06/2024
Next-generation Sequencing Services Market to be Worth $24.44 billion by 2031 -…
The growth of this market is mainly attributed to the reduced cost of NGS procedures, the development and approval of new targeted therapies, the rising prevalence of cancer, partnerships between NGS service providers and pharmaceutical companies, the high cost of sequencing infrastructure, and technological advancements in NGS. In addition, advancements in sequencing data analytics and the increasing applications of NGS in cancer and agri-genomics research are expected to offer significant…
PR Newswire
27/06/2024
Nexstim Plc Has Agreed on a Digitalization and Innovation Loan with Finnvera to…
Company Announcement, Helsinki, 27 June 2024 at 4:45 PM (EEST) Nexstim Plc Has Agreed on a Digitalization and Innovation Loan with Finnvera to Finance Product Development Project Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has agreed on an EUR 1.5 million digitalization and innovation loan with Finnvera. The loan has been implemented in cooperation with the European Investment Fund. The Company intends to use the loan for financing product development work of its NBS 6…
Nasdaq GlobeNewswire
27/06/2024
KFSH&RC Leads Global Healthcare Revolution with AI and Robotics
RIYADH, Saudi Arabia, June27, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) is at the forefront of the global AI and robotics revolution. These technological advancements, driven by Saudi Vision 2030, are set to unlock an estimated $15 billion to $27 billion in economic value for the Kingdom's medical sector by 2030, in addition to their pivotal role in streamlining processes and transforming patient care.Robotic-assisted surgeries are a...
Nasdaq GlobeNewswire
27/06/2024
Kameleoon Partners with North America's Largest Experimentation Event to Launch…
EXL+UNITE combines conference elements with networking, making it a premier destination for experimentation experts, product innovators, and growth leaders. The event fosters deep connections and shares practitioner-only knowledge. EXL+UNITE combines conference elements with networking, making it a premier destination for experimentation experts, product innovators, and growth leaders. The event fosters deep connections and shares practitioner-only knowledge. Event Highlights ...
PR Newswire
27/06/2024
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
®Index and the broad-market Russell 3000 ®Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. “We are pleased to be joining the Russell 2000 ®Index,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones...
Nasdaq GlobeNewswire
27/06/2024
Crown Laboratories, Inc. and BIOJUVE® Celebrate World Microbiome Day 2024
Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9271351-crown-laboratories-biojuve-celebrate-world-microbiome-day/ Experience the full interactive Multichannel News Release here:https://www.multivu.com/players/English/9271351-crown-laboratories-biojuve-celebrate-world-microbiome-day/ Genetics, stress, environmental factors, age, pathogens and more can create an imbalance in the skin's natural microbiome, but consumers can help...
PR Newswire
27/06/2024
STALICLA publishes pioneering phase 1b data on precision treatment for autism…
Press ReleaseSTALICLA's precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core symptomsGeneva, Switzerland – June 27, 2024– STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neuropsychiatric and neurodevelopmental disorders, today announced the publication of a landmark phase 1b study with STP1, a novel...
Nasdaq GlobeNewswire
27/06/2024
Fortrea Launches AI Innovation Studio to Galvanize Technology and Human…
The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research process by equipping and empowering people to focus on the critical human element of clinical trials.“Patients around the world are waiting for novel, life-changing treatments. With AI, we now have the power—and the obligation—to help deliver solutions to them faster,” said Fortrea's Chief Information Officer Alejandro Martinez...
Nasdaq GlobeNewswire
27/06/2024
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic…
SAN DIEGO and CALGARY, AB, June 27, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). The FDA supports progression-free survival as…
PR Newswire
27/06/2024
ZINZINO AB (PUBL.): ZINZINO ACQUIRES 49% OF CYPRIOT OLIVE OIL PRODUCER CLEANTHI…
The business is currently run on a small scale, with most of the production going to Zinzino's existing products R.E.V.O.O. and BalanceOil Premium. Through the partnership, Zinzino gains access to Cleanthi's IP rights, which opens up opportunities to develop and increase brand protection for Zinzino's BalanceOil, the product group that currently accounts for about 60% of the Group's total revenue. The business is currently run on a small scale, with most of the production going to Zinzino's...
PR Newswire
27/06/2024
Faucet Market to Reach $118.4 billion, Globally, by 2035 at 7.6% CAGR: Allied…
Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/2448 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/2448 Prime determinants of growth The faucet market is driven by increase in urbanization, population growth, and rise in residential and commercial construction activities. Rapid urbanization leads to higher demand for housing and infrastructure, resulting in a greater need for...
PR Newswire
27/06/2024
Release Therapeutics Announces New CEO to Drive Best-in-Class CNS Innovation
The appointment aligns with the company's recent strategic pivot towards treating genetic disorders of the CNS without gene therapy 1With over 25 years' experience in multinational pharma companies, including Takeda, Mundipharma International and Hoffmann-La Roche, Dr. Mehrling is an expert in developing novel oncology compounds from bench to bedside. During his tenure at MundiPharma International (2003–2013), he oversaw the clinical development, registration and launch of two major...
Nasdaq GlobeNewswire
27/06/2024
Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD…
EMERALD is an open-label, Phase I/II study which will investigate the safety and efficacy of engineered macrophage cell therapy, RTX001, in patients with decompensated liver cirrhosis. The primary analysis will focus on safety and major clinical events including death. The study will also evaluate biomarkers such as the Model for End-Stage Liver Disease (MELD) score which is used to assess disease severity and prioritise patients for a transplant. The EMERALD study will initiate in Q3 2024. ...
PR Newswire
27/06/2024
Tom Tacon appointed Business Unit Director of Bionical Virtual Engagement
At Daichi Sankyo, where he has worked since 2017, Tom spearheaded a multi-channel marketing approach – including setting up a virtual sales force, creating bespoke digital sales content and leading field sales teams. He has been involved in several highly successful UK product launches, both as a Regional Business Director (2017 – 2022) and more recently as the Brand Manager within their important cardiovascular franchise. At Daichi Sankyo, where he has worked since 2017, Tom spearheaded a...
PR Newswire
27/06/2024
Amsino Medical Group announces transformational investment from Novo Tellus
"We're excited to renew a long-term partnership with Novo Tellus" said Dr. Richard Y. Lee, Chairman and CEO of Amsino Medical Group, noting that "Novo Tellus has proven itself as a growth partner for Amsino before, and shares our fundamental commitment to delivering dependable innovation and value to our customers around the world." "We're excited to renew a long-term partnership with Novo Tellus" said Dr.Richard Y. Lee, Chairman and CEO of Amsino Medical Group…
PR Newswire
27/06/2024
Roche expands access to cervical cancer screening tools with two new WHO…
The World Health Organization (WHO) has awarded Roche's human papillomavirus (HPV) test prequalification designations for use on the cobas 5800 System and for self-collected samples on the cobas 5800, 6800 and 8800 Systems. These designations build upon last June's WHO prequalification that included the cobas HPV test for use on the cobas 6800 and 8800 Systems.WHO prequalification enables low- and middle-income countries (LMICs) to use Roche HPV screening solutions, including...
Nasdaq GlobeNewswire
27/06/2024
CARBIOS and Zhink Group enter official discussions for long-term partnership to…
This partnership would allow Zhink Group to meet its leadership ambitions through increased recycled PET capacities and sustainable competitiveness by offering recycled PET from enzymatic recyclingThis agreement confirms strong traction for CARBIOS biorecycling technology in China, the world's leading PET producerBased in China, the future plant will depolymerize minimum 50k tons of PET waste per year, with potential to expand capacities, to serve regional and global packaging and...
Nasdaq GlobeNewswire
27/06/2024
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or…
Company AnnouncementApproval based on results from Phase 1/2 EPCORE ®NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL EPKINLY offers an off-the-shelf, T-cell engaging treatment option that enables treatment across practice settings to address high clinical need EPKINLY is the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma...
Nasdaq GlobeNewswire
27/06/2024
Vascular Malformations Market to Grow Substantially by 2034, Assesses…
Key Takeaways from the Vascular Malformations Market Report Key Takeaways from the Vascular Malformations Market Report Discover which therapies are expected to grab the major vascular malformations market share @Vascular Malformations Market Report Vascular Malformations Overview Vascular malformations refer to abnormalities in blood vessels that develop during embryonic or fetal development. These malformations can occur anywhere in the body and are typically present from...
PR Newswire
26/06/2024
Press Release: Dupixent positive phase 3 data in children one to 11 years of age…
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one yearDupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group Paris and Tarrytown, NY, June 26, 2024. The New England Journal of Medicinehas publishedresults...
Nasdaq GlobeNewswire
26/06/2024
SMISS Asia Pacific 2024 Congress and training program
Press release Ecully, June 26, 2024 – 6 p.m. Hands-on surgical training in Hong Kong at the SMISS Asia Pacific 2024 Congress The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, participated in the 4thSMISS Asia Pacificcongress, dedicated to minimally invasive surgery, held in Hong Kong on June 13 and 14. Spineway was a Bronze Sponsor of the event, where the Group presented its ESP (cervical and lumbar) prostheses through...
Nasdaq GlobeNewswire
26/06/2024
Valneva Announces Successful Outcome of its Combined General Meeting and…
Saint-Herblain (France), June 26, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM) held today in Lyon, France.Among the adopted resolutions were approval of the 2023 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, and the...
Nasdaq GlobeNewswire
26/06/2024
EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for…
Press ReleaseAgreement with Sanofi on a 200 M€ investment through a Perpetual Subordinated Hybrid Bond, upon the completion of the ongoing discussions to amend and extend the current Revolving Credit Facility75 to 80 M€ annual run-rate incremental Core EBITDA targeted by the end of 2027, driven by the end of higher value API and CDMO offering, a streamlined industrial footprint, and significant cost reductions Brindisi site expected to progressively resume shipments...
Nasdaq GlobeNewswire
26/06/2024
Altri Comunicati
